On 1 April 2020, OSE announced that the primary endpoint was met in the predefined step 1 analysis of the Phase III Atalante 1 trial with OSE’s cancer vaccine Tedopi in HLA-A2 positive, non-small cell lung cancer (NSCLC) patients after they failed checkpoint inhibitors (CPIs, anti-PD-1 or anti-PD-L1). The patients (n=99) were randomised and received treatment at least 12 months before step1 analysis. The 12-month survival rate in the Tedopi arm was 46% (29 out of 63; CI 33–59%), w
07 Apr 2020
OSE Immunotherapeutics - Positive Tedopi step 1, rethinking its future
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OSE Immunotherapeutics - Positive Tedopi step 1, rethinking its future
OSE Immunotherapeutics SA (OSE:PAR) | 0 0 0.0%
- Published:
07 Apr 2020 -
Author:
Dr Jonas Peciulis -
Pages:
6
On 1 April 2020, OSE announced that the primary endpoint was met in the predefined step 1 analysis of the Phase III Atalante 1 trial with OSE’s cancer vaccine Tedopi in HLA-A2 positive, non-small cell lung cancer (NSCLC) patients after they failed checkpoint inhibitors (CPIs, anti-PD-1 or anti-PD-L1). The patients (n=99) were randomised and received treatment at least 12 months before step1 analysis. The 12-month survival rate in the Tedopi arm was 46% (29 out of 63; CI 33–59%), w